BKT-300 / Biokine Therap - LARVOL DELTA

Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway in Pancreatic Cancer Free (AACRPanCa 2025) - "Importantly, BKT300 synergized with 5FU and irinotecan to induce cancer cell death, both agents are the standard of care for treatment of pancreatic cancer patients. In vivo studies in PDAC mouse models demonstrated significant tumor growth inhibition and tumor regression, underscoring the therapeutic promise of BKT300 for PDAC. Overall, BKT300 presents a novel approach to tackling PDAC by directly targeting PRC1, potentially improving outcomes in PDAC cases with high PRC1 expression and resistance to conventional therapies."

Oncology • Pancreatic Cancer • Solid Tumor • CDC25C • CDKN1A • GNRP • PRC1

Bkt300, a novel small molecule targeting the protein regulator of cytokinesis 1 pathway in hepatocellular carcinoma (AACR 2025) - "In vivo studies in two HCC mouse models demonstrated significant tumor growth inhibition and tumor regression, underscoring the therapeutic promise of BKT300 for HCC. Overall, BKT300 presents a novel approach to tackling HCC by directly targeting PRC1, potentially improving outcomes in HCC cases with high PRC1 expression and resistance to conventional therapies."

Hepatocellular Cancer • Oncology • Solid Tumor • CASP3 • CDC25C • CDKN1A • GNRP • PRC1

BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. (PubMed, Res Sq) - "BKT300 treatment led to 98% of tumor growth inhibition and 89.4% of tumor regression in mouse xenograft AML models, without notable impacts on normal hematopoiesis or biochemistry, even at high doses. As a first-in-class targeted therapy, BKT300 presents a promising new treatment option for advanced AML."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • CASP3 • CDC25C • CDKN1A • GNRP • PRC1

Novel anti-cancer small molecule targeting the protein regulator of cytokinesis pathway (AACR 2024) - "Beyond its single agent activity, BKT300 was shown to synergize with standard of care (SoC) treatments, including anti PD-1 immunotherapy, BCL-2 inhibitor (Ventoclax), topoisomerase I inhibitor (Irinotecan) topoisomerase II inhibitor (Doxorubicin), anti-metabolite Fluorouracil (5-FU) and alkylating agent (Temozolomide). BKT300 is a novel, first in class, targeted anti-cancer treatment that inhibits the activity of the scaffold protein PRC1. BKT300 is expected to provide a new treatment option to, the high unmet medical need of, advanced difficult to treat cancers, specifically ones that overexpress PRC1 and CDC25C."

IO biomarker • Breast Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • CASP3 • CDC25C • CDKN1A • GNRP • PRC1